QUATRX'S FISPEMIFENE TRIAL PROCEEDS

QuatRx Pharmaceuticals has announced the initiation of a Phase II clinical trial for fispemifene, the company's product candidate for the treatment of the symptoms of andropause.

Fispemifene is the company's product candidate for the treatment of the symptoms of andropause. This first randomized, double-blind, placebo-controlled, parallel group Phase II study of fispemifene in the treatment of low testosterone in older men will seek to enroll approximately 100 patients at approximately 20 study sites in the U.S. Patients will receive either 100, 200, or 300 mg fispemifene or placebo for 28 days.